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ORIGINAL ARTICLE
Codeine-induced hyperalgesia and allodynia: investigating the
role of glial activation
JL Johnson1, PE Rolan1,2,3, ME Johnson4, L Bobrovskaya4, DB Williams4, K Johnson5, J Tuke6 and MR Hutchinson7
Chronic morphine therapy has been associated with paradoxically increased pain. Codeine is a widely used opioid, which is
metabolized to morphine to elicit analgesia. Prolonged morphine exposure exacerbates pain by activating the innate immune toll-
like receptor-4 (TLR4) in the central nervous system. In silico docking simulations indicate codeine also docks to MD2, an accessory
protein for TLR4, suggesting potential to induce TLR4-dependent pain facilitation. We hypothesized codeine would cause TLR4-
dependent hyperalgesia/allodynia that is disparate from its opioid receptor-dependent analgesic rank potency. Hyperalgesia and
allodynia were assessed using hotplate and von Frey tests at days 0, 3 and 5 in mice receiving intraperitoneal equimolar codeine
(21 mg kg− 1), morphine (20 mg kg− 1) or saline, twice daily. This experiment was repeated in animals with prior partial nerve injury
and in TLR4 null mutant mice. Interventions with interleukin-1 receptor antagonist (IL-1RA) and glial-attenuating drug ibudilast
were assessed. Analyses of glial activation markers (glial ﬁbrillary acid protein and CD11b) in neuronal tissue were conducted at the
completion of behavioural testing. Despite providing less acute analgesia (P= 0.006), codeine induced similar hotplate hyperalgesia
to equimolar morphine vs saline (−9.5 s, Po0.01 and − 7.3 s, Po0.01, respectively), suggesting codeine does not rely upon
conversion to morphine to increase pain sensitivity. This highlights the potential non-opioid receptor-dependent nature of codeine-
enhanced pain sensitivity—although the involvement of other codeine metabolites cannot be ruled out. IL-1RA reversed codeine-
induced hyperalgesia (Po0.001) and allodynia (Po0.001), and TLR4 knock-out protected against codeine-induced changes in pain
sensitivity. Glial attenuation with ibudilast reversed codeine-induced allodynia (Po0.001), and thus could be investigated further as
potential treatment for codeine-induced pain enhancement.
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INTRODUCTION
Opioid analgesics, used medicinally for millennia, remain vital in
pain management. However, convincing preclinical and mounting
clinical evidence suggests that long-term opioid use may
paradoxically increase pain resulting in opioid-induced
hyperalgesia.1 Opioid-induced hyperalgesia has been reported
following the administration of a range of opioids, yet it has not
been established if the ‘weak’ opioid codeine, can induce this
phenomenon. Codeine-induced hyperalgesia is of particular
interest, as in many regions codeine is available over-the-
counter leading to widespread, unregulated consumption.2,3
Codeine is the most frequently used opioid in several European
countries,4,5 and although most guidelines recommend only
short-term codeine treatment, pharmacoepidemiological evi-
dence indicates that 410% of patients prescribed codeine
consume more than the 120 deﬁned daily doses per year,
indicating chronic use.6 Codeine has low afﬁnity for μ-opioid
receptors, compared with other opioid analgesics,7 and is
considered a prodrug, dependent on transformation to morphine
to relieve pain.8
Once absorbed, codeine undergoes partial O-demethylation to
morphine via polymorphic cytochrome P450 isoenzyme 2D6
(CYP2D6).9,10 Most individuals convert ~10% of an oral codeine
dose to morphine.10 In mice, information regarding the
metabolism of codeine is incomplete, yet O-demethylation of
metoprolol, a typical human CYP2D6 substrate, is similar to that
seen in human liver microsomes,11 providing evidence that BALB/
c mice are an acceptable model to assess clinically relevant
codeine pharmacodynamics.
Numerous opioid-receptor-dependent neuronal mechanisms of
opioid-induced hyperalgesia have been proposed (see Ossipov
et al.12 for review), however, substantial preclinical evidence
establishes that morphine activates not only classical opioid
receptors, but also toll-like receptor-4 (TLR4) on glia, triggering
proinﬂammatory mediator release, initiating a cascade of events
that enhance nociception.13 While neuronal morphine actions are
analgesic, concurrent production of neuroexcitatory substances by
glial cells (for example, astrocytes, microglia) counteracts this
analgesia, to eventually increase pain. Thus, with increasing
morphine dose and/or duration, TLR4-dependent glial reactivity
increases reducing the analgesic efﬁcacy and ultimately leading to
allodynia and hyperalgesia.14
This TLR4-glial hypothesis has been established for morphine15
and oxycodone16 but remains to be tested for codeine. It is
plausible that codeine may induce hyperalgesia indirectly by
acting as a prodrug for morphine delivery. Insufﬁcient evidence
exists to allow the use of a codeine O-demethylation inhibitor to
test whether the conversion to morphine is solely responsible for
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any hyperalgesia observed in mice. Instead, here we compared
hyperalgesia precipitated by equimolar doses of codeine and
morphine. Hypothesizing opioid-induced hyperalgesia to be dose-
dependent,17,18 if codeine were only able to facilitate pain once
metabolized to morphine, then signiﬁcantly less hyperalgesia
would be expected in animals receiving codeine vs morphine, as
only a minor proportion of the codeine dose is converted to
morphine.
In silico docking simulations suggest that codeine docks to TLR4
accessory protein MD2,19 in a manner similar to morphine,15,20
indicating codeine has the potential to trigger TLR4-dependent
pain enhancement. Owing to codeine’s lower μ-opioid receptor
afﬁnity, higher doses are required relative to morphine to produce
equianalgesia. If codeine activates TLR4, greater glial activation
could occur following equianalgesic codeine vs morphine, as a
greater number of molecules must be administered to obtain the
same therapeutic response. Thus, we hypothesize that the risk
(hyperalgesia) to beneﬁt (analgesia) ratio is greater for codeine
compared with morphine.
Objectives
The objectives of the experiments presented in this manuscript
were as follows: to determine whether chronic codeine adminis-
tration induces hyperalgesia to the same degree as chronic
morphine administration, to ascertain if partial nerve injury primes
for codeine-induced hyperalgesia, to investigate the roles of
proinﬂammatory cytokine interleukin-1 and TLR4 in the develop-
ment of codeine-induced pain enhancement and ﬁnally to test the




Pathogen-free adult male wild-type BALB/c mice were obtained from the
University of Adelaide Laboratory Animal Services (Adelaide, SA, Australia).
Mice were housed in temperature (18–21 °C) and light-controlled (12 h
light/dark cycle; lights on at 0700 h) rooms with standard rodent food and
water available ad libitum. After arrival, the mice were allowed to acclimate
to the facility for at least 5 days and were subsequently handled for a
further 5 days before testing. All procedures were approved by the Animal
Ethics Committee of the University of Adelaide and were conducted in
accordance with the NHMRC Australian Code of Practice for the Care and
Use of Animals for Scientiﬁc Purposes and the guidelines of the Committee
for Research and Ethical Issues of International Association for the Study
of Pain.
Drugs
All treatments were administered via intraperitoneal injection at a volume
of 10ml kg− 1. Morphine hydrochloride (McFarlan Smith, Sydney, NSW,
Australia) in 0.9% saline was administered at 20mg kg− 1 (base-corrected).
Codeine phosphate (GlaxoSmithKline, Melbourne, VIC, Australia) in 0.9%
saline, was administered at 21mg kg− 1 (base-corrected equimolar dose to
morphine). Anakinra (Kineret, Amgen, Thousand Oaks, CA, USA), a
recombinant, nonglycosylated form of the human interleukin-1 receptor
antagonist (IL-1RA) in 0.9% saline was administered at 100mg kg− 1.
Ibudilast (Medicinova, San Diego, CA, USA) in 35% polyethelene glycol 400
(BDH Laboratory Supplies, Poole, England) in 0.9% saline was administered
at 15mg kg− 1. As ibudilast was administered in a single intraperitoneal
injection with concomitant codeine or morphine, the total dose volume for
both drugs together was adjusted to 10ml kg− 1 for consistency between
experiments. An equal volume of saline 0.9% was administered to control
animals in Experiments 1, 2, 3 and 4, whereas control animals in
Experiment 5 received 35% polyethylene glycol in 0.9% saline.
Drug administration
The morphine dose of 20mg kg− 1 used throughout the experiments
outlined below was based upon that previously used in our laboratory to
induce thermal hyperalgesia. The codeine dose was calculated to be
equimolar to morphine, not equianalgesic. As brieﬂy discussed in the
introduction, only ~10% of the codeine dose is thought to be metabolized
to morphine in vivo, thus when codeine 21mg kg− 1 is administered, the
animal will be exposed to substantially less morphine than when dosed
with morphine 20mg kg− 1.
Experiments 1a and 1b: Assessment of codeine-induced hyperalgesia and
allodynia and impact of prior partial nerve injury. In part 1a, wild-type mice
were randomly allocated to receive codeine (n=8), morphine (n= 8) or
saline (n= 8) twice daily for 4 days. In part 1b, all mice underwent a
modiﬁed version of the chronic constriction injury surgery to induce mild
allodynia, as described below. Two weeks post surgery, wild-type mice
were randomly allocated to receive codeine (n=8), morphine (n= 8) or
saline (n= 8) twice daily for 4 days. Behavioural assessments were
conducted at baseline, before dosing, on day 3 and in the morning
of day 5.
Experiment 2: Comparison of acute analgesia between codeine and
morphine. Wild-type mice (n= 8) were randomized to receive a single
dose of codeine, morphine and saline on three respective testing days
separated by 1-week washout periods. Hotplate testing was conducted
three times and averaged to establish baseline sensitivity, and repeated at
15, 30, 40, 50, 60, 75 and 90min post dose.
Experiment 3: Interleukin-1 receptor antagonist intervention. Wild-type
mice were randomly allocated to a 2 × 2 design of 2 (codeine vs morphine;
twice daily for 4 days) × 2 (IL-1RA vs saline; morning of day 5, 30 min before
behavioural testing) n= 8 per group. Behavioural assessments were
conducted at baseline, before dosing on day 3 and in the morning
of day 5.
Experiment 4: Assessment of codeine-induced hyperalgesia and allodynia in
TLR4 null mutant (TLR4− /− ) mice. TLR4 − /− mice were randomly
allocated to receive codeine (n= 8), morphine (n= 8) or saline (n=8) twice
daily for 4 days. Behavioural assessments were conducted at baseline,
before dosing on day 3 and in the morning of day 5.
Experiment 5: Glial attenuating intervention. Wild-type mice were ran-
domly allocated to a 2 × 2 design of 2 (codeine vs morphine; twice daily for
4 days) × 2 (ibudilast vs PEG400; days 3 and 4 twice daily) n=8 per group.
Behavioural assessments were conducted at baseline, before dosing, on
day 3 and in the morning of day 5.
Partial nerve injury surgery
The Grace model,21 a modiﬁed version of the chronic constriction injury
model of sciatic nerve injury22 was performed at mid-thigh level of the left
hind leg under isoﬂurane anaesthesia (3% in oxygen). Brieﬂy, the sciatic
nerve was gently isolated with glass instruments and a single sterile
chromic gut suture (cuticular 4-0 chromic gut, FS-2; Ethicon, Somerville, NJ,
USA) was loosely tied around the sciatic nerve. The superﬁcial muscle over
the nerve was closed and three additional lengths of chromic gut were
placed subcutaneously. The Grace model, in which a single chromic gut
suture is placed around the sciatic nerve (N) and three pieces of chromic
gut are placed subcutaneously (S) is designated N1S3, and creates a mild
pain state.21 All the surgery was performed using aseptic surgical
techniques with sterilized instruments. Animals were monitored post-
operatively until ambulatory before being returned to their home cage and
inspected daily for signs of infection. No such cases occurred in this study.
Although rescue morphine analgesia was on hand to administer following
the surgery if an adverse event occurred, no such additional analgesia was
required.
Behavioural testing
All behavioural testing was conducted during the light phase of the light/
dark cycle and followed at least two habituations to the testing
environment. The hotplate test and the von Frey test, two robust, well-
established methods for assessing opioid analgesia and nociceptive
sensitivity in rodents, were selected for use in this study as such tests
are simple to conduct and repeated testing can be performed, allowing
each animal to function as its own matched control.23
Allodynia assessments. The von Frey test was performed within the sciatic
innervation region of both hind paws as previously described in detail.24
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Brieﬂy, mice were placed in individual cylindrical plastic cubicles (10 cm
D×15 cm H) with sufﬁcient room to move freely on a wire mesh (6
mm×6mm) platform and allowed to acclimate for ~20min. A logarithmic
series of six calibrated von Frey monoﬁlaments (Touch Test Sensory
Evaluator Kit, St Louis, MO, USA), with bending forces that ranged from
0.02–0.4 g, were used to deliver the mechanical stimuli to the left and right
hind paws in a random order. Each ﬁlament was applied to the left and
right hind paw 10 times, and the number of paw-withdrawal responses
elicited was recorded. Testing was conducted blind to treatment group
allocation.
All animal assessments were conducted at baseline, before drug, dosing
on day 3 of the experimental period and in the morning of day 5 of the
experimental period. For animals in Experiment 2, additional assessments
were conducted on days 3, 7, 11 and 14 post surgery, before
randomization to treatment.
Hyperalgesia assessments. In all experiments, hotplate assessments were
conducted at baseline, before morning drug dosing on day 3 and the
morning of day 5, after von Frey assessments. Mice were placed on a
hotplate maintained at 50 ± 0.2 °C,25 a clean glass cup was placed over the
animal and the latency to paw withdrawal (seconds) was recorded. Mice
had sufﬁcient room to move freely while under the glass cup. Baseline
withdrawal values were calculated from an average of three consecutive
latencies, measured at 10min intervals. A pre-determined cut-off time of
60 s was imposed to prevent tissue damage.25 Mice were immediately
removed from the hotplate surface following the end of a trial due to paw-
withdrawal response or elapsed cut-off time.
Western blot analysis of GFAP and CD11b
Four animals from each treatment group were anaesthetized with
intraperitoneal sodium pentobarbital (Abbott Laboratories, Chicago, IL,
USA) and transcardially perfused with phosphate-buffered saline to ﬂush
blood cells from the central nervous system tissue. The lumbar section
(L4 to L6) of the spinal column and trigeminal ganglia were dissected out,
immediately snap-frozen in liquid nitrogen and stored at −70 °C until
processing. In preparation for the analysis, samples were immersed in cell
lysis buffer containing 1% protease inhibitor cocktail (Sigma-Aldrich,
Sydney, NSW, Australia, catalogue # P8340), sonicated then centrifuged at
14 000 r.p.m. for 5 min. The supernatant was collected and the pellet
discarded. Bicinchoninic acid (BCA) assays were performed to determine
total protein concentration and subsequently the samples were diluted to
allow loading of 30 μg of protein per western blot well. Samples were run
on an 8 or 10% sodium dodecyl sulphate-polyacrylamide gel and
transferred to nitrocellulose using the wet transfer method. Membranes
were immunoblotted with glial ﬁbrillary acid protein (GFAP, 1:3000, Santa
Cruz Biotechnology, Dallas, TX, USA, catalogue #sc-6170) or cluster of
differentiation molecule 11b (CD11b, 1:2000, Santa Cruz Biotechnology,
catalogue #sc-6614) antibodies overnight at 4 °C. Blots were washed and
left to incubate with appropriate secondary antibodies for 1 h. Following a
1min incubation with the enhanced chemiluminescence detection
reagent, immunoblots were visualized using a LAS 4000 imaging system
(GE Healthcare, Little Chalfont, UK) for the detection of chemiluminescent
signals. The density of protein bands of interest were then quantiﬁed using
ImageQuant TL software (GE Healthcare). Subsequently membranes were
washed and then immunoblotted with β-actin antibody (1:10 000, Sigma-
Aldrich, catalogue #A3854) as a marker of total protein loaded per each
lane. GFAP and CD11b protein levels were normalized relative to β-actin
levels.
Statistical analysis
All data are presented as mean± s.e.m. unless otherwise noted. Statistical
analyses were performed using R via RStudio (Version 0.97.312, RStudio,
Boston, MA, USA)26 and GraphPad Prism (Version 6, GraphPad Software,
San Diego, CA, USA). Hotplate test data were analysed using linear mixed
effects modelling with the R packages lme4,27 followed by simultaneous
tests for general linear hypothesis and adjusted for multiple comparisons
using Tukey contrasts, with adjusted P-values reported using the single-
step method.28 A one-way repeated measures analysis of variance
(ANOVA), corrected with a post hoc Tukey’s multiple comparisons test,26
was used to analyse differences in acute analgesia between the treatment
groups in Experiment 2. For each von Frey test, von Frey ﬁlament number
was plotted against percentage response (number of withdrawals per 10
ﬁlament applications × 10), giving a slope and intercept for each animal at
each test time point using the R package ggplot2.29 Slope represents
percentage change in response as von Frey ﬁlament stiffness increases. A
positive slope indicates a greater percentage response to high von Frey
ﬁlament pressures vs low pressures, whereas a negative slope indicates a
greater percentage response to low von Frey ﬁlament pressures vs high
pressures, and as the slope approaches zero the percentage response to
low and high von Frey ﬁlament pressures become similar. The intercept is
an indicator of sensitivity to very low pressures; a greater intercept
indicates greater allodynia elicited by low pressures. Slope and intercept
were combined to form the allodynia outcome measure and analysed
using multivariate ANOVA tests.26 For simplicity, only von Frey results for
the left leg are presented as all the treatments and interventions were
delivered systemically or performed on the left side. Western blot results
were analysed using two-way ANOVA tests with Bonferroni post hoc tests
to adjust for multiple comparisons. Correlations between western blot data
and behavioural data were investigated using linear mixed effects
modelling,27 followed by AIC stepwise model selection using the stepAIC
function from the MASS library.30 P-values o0.5 and F-values 43 were
considered to indicate a signiﬁcant difference. All R code employed during
analysis is available upon request from the authors.
RESULTS
Experiments 1a and 1b: Assessment of codeine-induced
hyperalgesia and allodynia and impact of prior partial nerve injury
in wild-type mice.
Linear mixed effects modelling including data from both
Experiments 1a and 1b highlighted signiﬁcant effects of drug
(F= 12.6), day (F= 36.9) and surgery (F= 114.0) alone, as well as
signiﬁcant drug:day (F= 8.5) and day:surgery (F= 16.0) interaction














































Figure 1. Experiment 1a: mice received intraperitoneal codeine (21 mg kg− 1, n= 8), morphine (20mg kg− 1, n= 8) or saline (n= 8) twice daily
for 4 days. Hyperalgesia (hotplate) and allodynia (von Frey) were measured on days 0, 3 and 5. (a) Codeine and morphine signiﬁcantly reduced
hotplate paw-withdrawal latency at day 5 vs saline. (b) There was a signiﬁcant effect of drug on the development of allodynia in the codeine
group (total allodynia was measured by calculating the slope and intercept for the plot of percentage response (number of paw withdrawals
per 10 applications x 10) vs von Frey stimulus for each group). *Po0.05, **Po0.01.
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illustrated in Figure 1a, Tukey post hoc analyses revealed that
animals receiving codeine 21mg kg− 1 and morphine 20mg kg− 1
twice daily for 4 days displayed signiﬁcantly reduced paw-
withdrawal latency, indicative of hyperalgesia, on day 5 compared
with saline-treated wild-type mice (Po0.01 and Po0.01, respec-
tively). Paw-withdrawal latency was also reduced on day 5 vs
baseline within the codeine (Po0.001) and morphine (Po0.001)
groups. In Experiment 1b, partial nerve injury induced hyperalge-
sia at baseline in all groups, which was equivalent to that present
in the codeine and morphine groups who did not undergo
surgery on day 5 of the treatment. Basal hyperalgesia was present
to such a degree that further decreases in latency in post-surgery
animals receiving codeine (P= 0.5) or morphine (P= 0.9) on day 5
vs baseline, or between post-surgery mice receiving codeine
(P= 0.4) and morphine (P= 0.2) vs saline on day 5 did not reach
signiﬁcance (data not shown). No differences were detected
between codeine and morphine groups within Experiments 1a
and 1b on days 3 and 5.
Multivariate ANOVA of all von Frey data from Experiments 1a
and 1b combined on day 5 highlighted overall signiﬁcant effects
of both drug (P= 0.007) and surgery (Po0.001) on allodynia,
indicating that both taking codeine or morphine, or undergoing
surgery, increases sensitivity to non-noxious stimuli. In the codeine
groups, drug (P= 0.03, see Figure 1b) and surgery (Po0.001)
signiﬁcantly inﬂuenced allodynia, yet there was no signiﬁcant
surgery:drug interaction (P= 0.91), demonstrating that codeine-
induced allodynia did not differ between surgery and no-surgery
animals. In the morphine groups, although surgery alone had a
signiﬁcant effect on allodynia (Po0.001), drug (P= 0.08) did not
contribute to allodynia until surgery was factored in, as indicated
by a signiﬁcant surgery:drug interaction (P= 0.04). This signiﬁcant
surgery:drug interaction demonstrates that the development of
allodynia following morphine treatment differs in surgery animals
compared with no-surgery animals. Animals who received
morphine without surgery displayed lesser sensitivity to low von
Frey ﬁlament pressures than morphine animals who underwent
surgery; however, regardless of surgery status, both groups
receiving morphine displayed a high response rate to high von
Frey ﬁlament pressures.
Behavioural test results for codeine and morphine treatment
groups were compared with saline controls on day 5, as well as
their respective baseline ﬁndings, to control for learned or
conditioned behaviour to the testing procedures. However, such
factors are unlikely to inﬂuence results as no signiﬁcant change in
hotplate latency or response to von Frey ﬁlament stimulation was
observed in the saline animals across the 5 days of testing.
Experiment 2: Comparison of acute analgesia between codeine
21mg kg− 1 and morphine 20mg kg− 1
Acute codeine administration at 21 mg kg− 1 provided signiﬁcantly
less hotplate analgesia than morphine 20mg kg− 1 measured in
terms of area under the time-effect (paw-withdrawal latency/
analgesia) curve from 0–90min post dose, as shown in Figure 2.
Experiment 3: Interleukin-1 receptor antagonist intervention
A signiﬁcant overall effect of intervention (IL-1RA or saline) was
detected in both hotplate (Po0.001) and von Frey (Po0.001)
tests. As illustrated in Figure 3a1, both codeine and morphine
when given with saline only produced signiﬁcant hyperalgesia
(Po0.001 and Po0.001, respectively) at day 5 vs baseline. In
codeine and morphine animals receiving IL-1RA before the ﬁnal
hyperalgesia assessment on day 5, paw-withdrawal latency began
to return to baseline levels for both opioid groups, with morphine
+IL-RA vs morphine+saline (Po0.001) and codeine+IL-RA vs
codeine+saline (Po0.001) reaching signiﬁcance. In the von Frey
test, codeine and morphine, given with saline, established
allodynia on day 5 vs baseline (Po0.001 and Po0.001,
respectively). Partially established allodynia in codeine and
morphine groups was abolished by IL-RA on day 5, as depicted
in Figure 3a2.
Experiment 4: Assessment of codeine-induced hyperalgesia and
allodynia in TLR4− /− mice
Incorporating data from the no-surgery Experiment 1a mice, linear
mixed effects modelling found signiﬁcant effects of genotype
(TLR4− /− or wild type) alone (F= 7.6), as well as signiﬁcant drug:
genotype (F= 3.002) and genotype:day (F= 21.2) interactions
effects on hyperalgesia. Tukey post hoc analyses conﬁrmed no
signiﬁcant differences in paw-withdrawal latency in the hotplate
test between treatment groups on day 5 in TLR4− /− animals (see
Figure 3b1). Similarly, multivariate ANOVA revealed a signiﬁcant
effect of genotype (Po0.0001) on allodynia at day 5 and
demonstrated that TLR4− /− mice were protected against
changes in pain sensitivity in all treatment groups as shown in
Figures 3b2, b3 and b4.
Experiment 5: Glial attenuating intervention
A signiﬁcant overall effect of intervention (ibudilast or vehicle) was
detected in both hotplate (P= 0.002) and von Frey (P= 0.003) tests.
As shown in Figure 3c1, ibudilast signiﬁcantly increased paw-
withdrawal latency vs vehicle in the morphine group (P= 0.035).
The trend of hyperalgesia reversal following ibudilast in the
codeine group did not reach signiﬁcance vs vehicle (P= 0.246).
Codeine and morphine groups receiving vehicle on days 3 and 4,
in addition to their respective opioids, displayed allodynia
(Po0.001 and P= 0.009, respectively) at day 5 vs baseline.
Established allodynia in codeine and morphine groups was
abolished by ibudilast on day 5, as illustrated in Figure 3c2.
2.6 western blot analysis of GFAP and CD11b
Following ﬁnal behavioural testing bilateral trigeminal ganglion
tissue and the lumbar section of the spinal cord were dissected
and prepared for western blot analysis to investigate levels of
markers associated with reactivity of glial cells. Levels of CD11b, an
adhesion molecule marker for active macrophages and




























Figure 2. Experiment 2 (acute analgesia): mice (n= 8) were
randomized to receive a single codeine (21mg kg− 1), morphine
(20mg kg− 1) and saline dose on three separate occasions, separated
by a washout period of 1 week. Hotplate testing was performed at
baseline and 15, 30, 40, 60, 60 and 75min post dose and total
analgesia produced over the 0–90min testing period for each drug
was calculated to give area under the time-effect (analgesia) curve
(AUC). Codeine produced a greater AUC from 0–90min post dose vs
saline. Morphine produced a signiﬁcantly greater AUC from 0–
90 min post dose vs an equimolar dose of codeine. *Po0.05,
**Po0.01.
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reactive response of astrocytes and satellite glial cells after
exposure to an insult,33–35 were quantiﬁed.
When all drug treatment groups were taken together, partial
nerve injury surgery before opioid administration signiﬁcantly
increased GFAP expression in the trigeminal ganglion (Po0.01)
and spinal cord (P= 0.02). However, no overall effect of drug was
detected (P= 0.3). Signiﬁcant effects of both surgery (P= 0.02) and
drug (Po0.01), and a surgery:drug (Po0.01) interaction were
found on CD11b levels in the spinal cord, although these appear
to be driven largely by a difference within the codeine group.
Drug also had a signiﬁcant overall effect on CD11b in the
trigeminal ganglion (Po0.01). In Experiments 1a and 1b, linear
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modelling with stepwise model selection by AIC demonstrates
that spinal cord GFAP, CD11b and the interaction between spinal
cord GFAP and CD11b are able to predict 82% of the variation in
hotplate test scores in the morphine groups, and 35% of hotplate
test score variability in the codeine groups, whereas no model
based upon the spinal cord markers was able to account for
hotplate test variability in the saline-treated mice.
Within TLR4− /− animals, codeine and morphine did not
increase GFAP or CD11b at either site assessed. The TLR4− /−
mice displayed reduced CD11b levels in the spinal cord, yet
compared with wild-type animals, spinal GFAP was not altered
(P= 0.5), and, in the trigeminal ganglion, CD11b (Po0.01) and
GFAP (Po0.01) appeared elevated. Intervention with ibudilast did
not bring about any differences in GFAP or CD11b in the spinal
cord; yet in the trigeminal ganglion, codeine produced signiﬁcant
increases in GFAP (Po0.01) and CD11b (Po0.01) vs morphine,
which were abolished following ibudilast administration. A
summary of the relevant pair-wise comparisons in glial activation
markers throughout all experiments is presented in Table 1
(Speciﬁc comparisons between partial nerve injury+drug and
drug-only (no surgery) animals are not presented because no
differences in hyperalgesia or allodynia were observed after drug
treatment). Representative western blot images are presented in
Figure 4.
DISCUSSION
In this study, we have demonstrated that codeine is able to induce
hyperalgesia and allodynia to the same degree as equimolar
morphine. This suggests that codeine may not rely solely upon
metabolism to morphine to produce hyperalgesia, as if it was only
the morphine metabolite of codeine causing pain sensitivity
changes; signiﬁcantly less hyperalgesia and allodynia would be
expected in the codeine group, given that only a small proportion
of the codeine dose is converted to morphine. The possibility that
codeine is largely being converted to morphine in this mouse
strain is unlikely as the hotplate test conﬁrmed that codeine
provides signiﬁcantly less acute analgesia over 90 min post dose
than morphine at an equimolar dose in male BALB/c mice,
however, we cannot rule out the involvement of other codeine
metabolites in the development of increased pain sensitivity. TLR4
and IL-1β appear to have important roles in the development of
hyperalgesia as genetic lack of TLR4 and administration of an
IL-1RA both abolished codeine-induced increases in pain sensitiv-
ity. Furthermore, attenuating glial activation with ibudilast
reversed partially established codeine-induced allodynia.
To model the clinical situation in which opioids are adminis-
tered to patients with an increased basal pain state, we ﬁrst
performed partial nerve injury surgery to prime animals before
codeine administration. Relative to the hypothesized involvement
of glial cells in morphine-induced hyperalgesia, we expected
surgery to ﬁrst prime the glial cells, triggering them to respond
faster with greater magnitude, when subsequently activated
following opioid administration.36 We found that surgery pro-
duced hyperalgesia and allodynia at baseline, and although
codeine and morphine animals displayed a trend towards a
further increase in pain sensitivity, this did not reach signiﬁcance,
likely owing to a ﬂoor effect of the behavioural testing employed.
Figure 3. (a) Experiment 3: mice received intraperitoneal (i.p.) codeine (n= 16, 21mg kg− 1) or morphine (n= 16, 20mg kg− 1) twice daily for
4 days. Hyperalgesia (hotplate) and allodynia (von Frey) were measured on days 0, 3 and 5. Thirty minutes before assessments on day 5, half of
the mice in each drug group received i.p. interleukin-1 receptor antagonist (IL-1RA, 100mg kg− 1) and the remaining half received saline. (a1)
IL-1RA abolished decreases in paw-withdrawal latency in both the codeine and morphine groups at day 5 vs groups receiving saline. (a2)
IL-1RA signiﬁcantly attenuated allodynia induced by codeine and morphine on day 5 vs saline in the left hind paw. (b) Experiment 4: toll-like
receptor-4 null mutant mice received i.p. codeine (n= 8, 21mg kg− 1), morphine (n= 8, 20mg kg− 1) or saline (n= 8) twice daily for 4 days.
Hyperalgesia (hotplate) and allodynia (von Frey) were measured on days 0, 3 and 5. (b1) Codeine (P= 0.996) and morphine (P40.99) did not
alter hotplate paw-withdrawal latency at day 5 vs baseline. Allodynia did not change signiﬁcantly over time in (b2) saline (P= 0.09), (b3)
codeine (P= 0.051) or (b4) morphine (P= 0.21) groups. (c) Experiment 5: mice received i.p. codeine (n= 16, 21 mg kg− 1) or morphine (n= 16,
20mg kg− 1) twice daily for 4 days. On days 3 and 4, half of the mice in each group received i.p. ibudilast (15 mg kg− 1) and the remaining half
received vehicle twice daily. Hyperalgesia (hotplate) and allodynia (von Frey) were measured on days 0, 3 and 5. (c1) Ibudilast reversed
decreases in hotplate paw-withdrawal latency in morphine but not codeine (P= 0.2) animals at day 5 vs groups receiving saline in addition to
their respective opioid. (c2) Ibudilast signiﬁcantly attenuated allodynia induced by codeine and morphine in the von Frey test on day 5 vs
saline in the left hind paw. Total allodynia was measured by calculating the slope and intercept for the plot of number of paw withdrawals per
10 applications vs von Frey stimulus for each group. ***Po0.001.
Table 1. Fold change between treatment groups and comparator controls in glial ﬁbrillary acidic protein (GFAP) and cluster of differentiation
molecule 11b (CD11b) levels relative to β-actin, in the spinal cord and trigeminal ganglion.
Treatment group Comparator group Fold change (P-value)
Spinal cord GFAP Spinal cord CD11b Trigeminal ganglion GFAP Trigeminal ganglion CD11b
Codeine only Saline only 0.93 (40.99) 1.59 (o0.01)** 0.60 (0.14) 0.25 (o0.01)**
Morphine only Saline only 0.82 (40.99) 0.73 (0.23) 0.58 (40.12) 0.67 (0.35)
Saline TLR4 − /− Saline only 1.47 (0.32) 0.46 (o0.01)** 6.33 (0.02)* Unavailablea
Codeine TLR4 − /− Saline TLR4 − /− 0.60 (0.15) 0.97 (40.99) 0.83 (40.91) 0.61 (0.03)*
Morphine TLR4 − /− Saline TLR4 − /− 0.43 (0.03)* 0.74 (0.56) 0.25 (40.07) 1.03 (0.99)
Codeine+ibudilast Codeine+vehicle 1.32 (0.29) 1.66 (0.14) 0.06 (0.01)* 0.18 (o0.01)**
Morphine+ibudilast Morphine+vehicle 1.34 (0.48) 1.17 (0.75) 1.78 (40.99) 1.78 (0.44)
Abbreviation: TLR4, Toll-like receptor-4. Codeine only, codeine TLR4− /− , codeine+ibudilast and codeine+vehicle animals received codeine intraperitoneal
(i.p.) 21mg kg− 1 twice daily for 4 days. Morphine only, morphine TLR4− /− , morphine+ibudilast and morphine+vehicle animals received morphine i.p.
20mg kg− 1 twice daily for 4 days. Saline only and saline TLR4 − /− animals received i.p. saline (equal volume to opioids) twice daily for 4 days. Codeine
+ibudilast and morphine+ibudilast received i.p. ibudilast 15mg kg− 1 (in 35% polyethelene glycol) twice daily on days 3 and 4, in addition to their respective
opioids. Codeine+vehicle and morphine+vehicle animals received i.p. 35% polyethelene glycol twice daily on days 3 and 4, in addition to their respective
opioids. All tissues samples were obtained on day 5 of the experimental protocols. Values o1 represent a reduction in marker level vs comparator whereas
values 41 represent an increase relative to comparator. aUnable to quantitate due to poor blot quality.
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As in prior experiments,21,37 partial nerve injury surgery
increased the overall levels of a marker of astrocyte activation,
GFAP,38 in the lumbar spinal cord. Administering morphine post
surgery further elevated lumbar astrocyte activation, concurring
with the results reported by Raghavendra et al.,37 who found a
greater magnitude of astrocyte activation following chronic
morphine administration in nerve-injured compared with sham-
operated rats, yet the same increase was not observed when
codeine was given post surgery. Interestingly, unlike previous
studies of morphine,37,39,40 we did not observe an increase in
markers of glial activation in no-surgery animals receiving
morphine, nor did we ﬁnd increased glial activation markers in
animals receiving chronic codeine, as compared with control
animals. The signiﬁcant hyperalgesia and allodynia present could,
however, result from glial activation that was not captured by our
tissue collection time point or proinﬂammation without pheno-
typic glial cell surface expression changes. While pain behaviour in
codeine and morphine animals was comparable, and both groups
were sensitive to the same pharmacological interventions
(indicating similar mediators are at play), linear modelling
suggests that molecular changes, inferred from the phenotypic
cellular expression markers, are not identical. Although cellular
surface markers represent only surrogates of activity, it is clear the
processes underlying opioid-induced changes in pain sensitivity,
resulting from the summation of μ-opioid receptor and TLR4
signalling cascades, are indeed complex, particularly following
codeine administration. Further studies with greater group
numbers for protein analysis and multiple tissue collection time
points may assist in clarifying proteomic results.
Toll-like receptor-4, which detects ‘danger signals’ and microbial
associated molecular patterns—such as lipopolysaccharide found
in the cell wall of gram-negative bacteria—is a key modulator in
innate immune system activation.41 In our study, mice lacking
TLR4 were protected against codeine-induced hyperalgesia and
allodynia. Protection against glial activation in TLR4− /− mice
could not be conﬁrmed as western blot results were inconclusive,
however, behavioural ﬁndings in TLR4− /− mice were robust and
agree with previous evidence that pharmacological blockade of
TLR4 using (+)-naloxone is able to signiﬁcantly attenuate
paradoxical morphine-induced increases in pain sensitivity.20
Once activated, glial cells release a range of proinﬂammatory
mediators such as the inﬂammatory cytokine IL-1β. Again aligning
with a glial activation hypothesis, we have demonstrated that
pharmacological antagonism of the IL-1 receptor using anakinra is
sufﬁcient to reverse codeine-induced hyperalgesia and allodynia.
These results also agree with literature indicating systemically
delivered IL-1RA enters the central nervous system42,43 and is able
to reinstate morphine analgesia in animals that display opioid
tolerance, a phenomenon which has previously been described as
a behavioural manifestation of opioid-induced hyperalgesia.44
Treatment with the glial-attenuating agent ibudilast45 reversed
codeine-induced allodynia. Ibudilast’s pharmacological actions
include inhibition of macrophage migration inhibitory factor46 and
phosphodiesterase 4 and 10 (and to a less extent 3 and 11).47 Both
these inhibitory actions are thought to contribute to its glial-
attenuating ability.48 Previously ibudilast has been shown to
potentiate the analgesic potency of morphine in tolerant
rodents.39 Given that blocking IL-1 reversed changes in pain
sensitivity, and ibudilast has been shown to prevent the release of
IL-1 from microglial cells,49 it is plausible that the reversal of
opioid-induced allodynia by ibudilast is brought about either
directly or indirectly through glial modulation. As a phosphodies-
terase inhibitor vascular reactivity, and therefore drug distribution,
could be altered following ibudilast administration. However, it is
unlikely that altered distribution accounts for the reduction in
morphine-induced hyperalgesia observed in this study as previous
experiments have demonstrated that ibudilast co-administration
does not alter morphine pharmacokinetics.39 Furthermore, multi-
ple studies have established that ibudilast co-administration
potentiates morphine analgesia, the opposite of what would be
expected if ibudilast resulted in reduced distribution of morphine
to the central nervous system.39,50
Although ibudilast has previously been reported to produce
slight sedation, reduced locomotor activity50 and reduced
sensitivity to touch,51 it is unlikely that these adverse effects—
which occur early (within 30min of dosing) and are transient51—
have inﬂuenced results, as all testing in our study was performed
16 h post ibudilast dose. While we could not conﬁrm that ibudilast
reduced the activation of lumbar spinal glial cells (which would
mediate hind paw allodynia), a reduction in glial-mediated
inﬂammation, independent of the cell surface markers assessed,
could account for our results. In the trigeminal ganglion, ibudilast
signiﬁcantly reversed substantial codeine-induced satellite glial
cell activation, indicating that the trigeminal ganglion glial cells
may be particularly sensitive to the glial-activating effects of
codeine, and ibudilast may be useful in attenuating activation at
this site.
We are conﬁdent that our behavioural results are reproducible
in male BALB/c mice, yet additional studies are required to
determine generalizability to females and other strains of mice, as
large variability in opioid response has been reported between
female and male rodents52 and among different mice strains.53
Regardless, results from previous preclinical studies investigating
opioid-induced hyperalgesia following morphine, methadone and
buprenorphine dosing have been replicated in human trials,
indicating that studies such as this do have positive predictive
value in the clinic. In these experiments, pain sensitivity was only
assessed the morning after opioid administration (~16h post-
dose), thus the hyperalgesia and allodynia displayed may be


























































Figure 4. (a) Representative western blot images for cluster of differentiation molecule 11b (CD11b), glial ﬁbrillary acid protein (GFAP) and β-
actin. Shows samples of the lumbar spinal cord of animals receiving intraperitoneal codeine (21 mg kg− 1) or saline, twice daily for 4 days.
Tissue samples collected on day 5 of the experimental protocol. (b) Fold change in lumbar spinal cord CD11b, normalized for β-actin, in
animals receiving codeine (21mg kg− 1) compared with saline controls; corresponds with band at 170 kDa in a. (c) Fold change in lumbar
spinal cord GFAP, normalized for β-actin, in animals receiving codeine (21mg kg− 1) compared with saline controls; corresponds with band at
50 kDa in a. **Po0.01.
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studies, additional testing shortly after opioid administration
would be of interest to determine if opioid tolerance was also
present.
The observation of equal hyperalgesia following equimolar
codeine and morphine administration has important clinical
implications, as although both drugs appear to increase pain to
the same degree, codeine provides only around one-tenth of the
analgesia that morphine provides when equal doses are given,
thus the risks:beneﬁt ratio may be higher for codeine than for
morphine. One example of a clinical pain state that is frequently
worsened following codeine use is medication overuse headache,
in which patients with an underlying primary headache disorder,
progress to experience chronic daily or near-daily headache.54 We
have previously hypothesized that glial priming due to recurrent
headaches may be responsible for the speciﬁc susceptibility to
opioid-induced chronic headache observed in patients with pre-
existing headache conditions.19 Given that the trigeminal gan-
glion is of particular importance in the pathophysiology of
migraine, the exaggerated satellite glial activation observed in
the ibudilast intervention experiment suggests that codeine may
be particularly detrimental in the management of this condition,
and additional studies that include assessment of facial allodynia
could provide a useful behavioural correlate to aid in interpreting
protein analysis results.
CONCLUSIONS
This study provides the ﬁrst preclinical evidence that repeated
doses of codeine, similar to morphine, are able to induce both
hyperalgesia and allodynia. Mechanistically, increased sensitivity
to pain following codeine administration may occur as a result of
TLR4 activation-dependent proinﬂammatory cytokine release by
glial cells. Glial attenuation with agents such as ibudilast, for which
the clinical safety is already established, may prove to be of use in
the clinical management of opioid-induced hyperalgesia.
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